Addendum
Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Addendum to Project A25-80
Report documents
-
Addendum
Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Addendum to Project A25-80
Dossier assessment
Indication:
First-line treatment of adult patients with unresectable or metastatic colorectal cancer with mismatch repair deficiency or high microsatellite instability
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-12-18 A G-BA decision was published.
Project details
- Project no.
- A25-135
- Commission
- Commission awarded on 28.10.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-135_en
Connected Projects
-
Dossier assessment
Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed